Context Therapeutics (CNTX) Change in Accured Expenses (2020 - 2026)

Context Therapeutics has disclosed Change in Accured Expenses across 7 years of filings, most recently posting -$1.5 million for Q1 2026.

• Change in Accured Expenses for Q1 2026 came in at -$1.5 million, down 265.58% year-over-year; the trailing twelve-month figure through Mar 2026 was $3.1 million (up 1288.76% YoY), and the FY2025 annual result was $4.2 million, up 775.44% from the prior year.
• Change in Accured Expenses came in at -$1.5 million for Q1 2026 at Context Therapeutics, down from $2.2 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $2.2 million in Q4 2025 to a low of -$1.5 million in Q1 2026.
• The 5-year median for Change in Accured Expenses is $206373.0 (2024), against an average of $179233.8.
• Across the five-year window, Change in Accured Expenses slumped 454.29% in 2024 and soared 21306.42% in 2025, its largest moves.
• Context Therapeutics' Change in Accured Expenses stood at -$222150.0 in 2022, then tumbled by 335.41% to -$967261.0 in 2023, then jumped by 98.94% to -$10276.0 in 2024, then jumped by 21306.42% to $2.2 million in 2025, then tumbled by 167.3% to -$1.5 million in 2026.
• The last three Change in Accured Expenses figures came in at -$1.5 million (Q1 2026), $2.2 million (Q4 2025), and $1.2 million (Q3 2025), per Business Quant data.